文章：

接受放射性配体治疗的胃肠胰神经内分泌肿瘤患者的监测与随访

Monitoring and Surveillance of Patients with Gastroenteropancreatic Neuroendocrine Tumors Undergoing Radioligand Therapy

原文发布日期：2 October 2023

DOI: 10.3390/cancers15194836

类型: Article

开放获取: 是

英文摘要：

Radioligand therapy (RLT) with [177Lu]Lu-DOTA-TATE is a standard of care for adult patients with somatostatin-receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Taking advantage of this precision nuclear medicine approach requires diligent monitoring and surveillance, from the use of diagnostic SSTR-targeted radioligand imaging for the selection of patients through treatment and assessments of response. Published evidence-based guidelines assist the multidisciplinary healthcare team by providing acceptable approaches to care; however, the sheer heterogeneity of GEP-NETs can make these frameworks difficult to apply in individual clinical circumstances. There are also contradictions in the literature regarding the utility of novel approaches in monitoring and surveilling patients with GEP-NETs receiving RLT. This article discusses the emerging evidence on imaging, clinical biochemistry, and tumor assessment criteria in the management of patients receiving RLT for GEP-NETs; additionally, it documents our own best practices. This allows us to offer practical guidance on how to effectively implement monitoring and surveillance measures to aid patient-tailored clinical decision-making.

摘要翻译： 

[¹⁷⁷Lu]Lu-DOTA-TATE放射性配体疗法（RLT）是生长抑素受体（SSTR）阳性胃肠胰神经内分泌肿瘤（GEP-NETs）成人患者的标准治疗方案。要充分发挥这种精准核医学方法的优势，需要从诊断性SSTR靶向放射性配体成像用于患者筛选，到治疗过程及疗效评估，进行严谨的监测与随访。已发布的循证指南为多学科医疗团队提供了可行的诊疗路径，但GEP-NETs的高度异质性往往使这些框架难以适用于个体化临床情境。此外，关于新型监测方法在RLT治疗GEP-NETs患者中的应用价值，现有文献亦存在矛盾观点。本文探讨了GEP-NETs患者接受RLT治疗过程中影像学评估、临床生化检测及肿瘤评价标准的最新证据，并记录了我们的临床实践方案，从而为如何有效实施监测随访措施、辅助制定个体化临床决策提供实用指导。

原文链接：

Monitoring and Surveillance of Patients with Gastroenteropancreatic Neuroendocrine Tumors Undergoing Radioligand Therapy